Target Price | $55.88 |
Price | $43.06 |
Potential |
29.76%
register free of charge
|
Number of Estimates | 16 |
16 Analysts have issued a price target Kymera Therapeutics Inc 2025 .
The average Kymera Therapeutics Inc target price is $55.88.
This is
29.76%
register free of charge
$106.00
146.17%
register free of charge
$36.00
16.40%
register free of charge
|
|
A rating was issued by 17 analysts: 13 Analysts recommend Kymera Therapeutics Inc to buy, 4 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Kymera Therapeutics Inc stock has an average upside potential 2025 of
29.76%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 78.59 | 58.29 |
67.82% | 25.83% | |
EBITDA Margin | -206.09% | -412.82% |
39.02% | 100.31% | |
Net Margin | -197.43% | -321.89% |
47.68% | 63.04% |
17 Analysts have issued a sales forecast Kymera Therapeutics Inc 2024 . The average Kymera Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Kymera Therapeutics Inc EBITDA forecast 2024. The average Kymera Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Kymera Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Kymera Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.52 | -3.05 |
12.20% | 21.03% | |
P/E | negative | |
EV/Sales | 39.86 |
6 Analysts have issued a Kymera Therapeutics Inc forecast for earnings per share. The average Kymera Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Kymera Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Kymera Therapeutics Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.